The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

A novel 3D-printed nanofiltration module delivers nearly double the saccharide recovery rate and lowers costs.

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.

Small biotechs are encouraged to develop robust processes early to avoid wasted time and increased costs on repeating scale-up.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

More analysis is needed to help manufacturers stop protein therapeutics from sticking to surfaces during downstream production operations.

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...

Cyclone is a portable gene-switch system that uses acyclovir to reversibly control gene expression with minimal toxicity.

Study reshapes view of how a common leukemia begins and could point to new therapeutic strategies targeting a common weakness.

Tumors were eradicated in 30% of mice receiving cGAS LNPs injected into the tumor, in combination with immune checkpoint blockade.